Venatorx Pharmaceuticals is a private company that is focused on the discovery and development of novel anti-infectives to treat multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral infections. The company name, Venatorx (ven-a-TOREX), derives from the Latin word “venator”, meaning ‘hunter’ and “rx”, the medical symbol for drugs. The pursuit, or “hunt”, for new drugs is the core mission of our company.
Founded in 2010, Venatorx Pharmaceuticals is a private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with multi-drug-resistant bacterial infections and hard-to-treat viral infections. Venatorx has built a world-class in-house research and development organization that has filed over 120 patents. Venatorx’s two lead antibacterial clinical-stage programs are intravenous (cefepime-taniborbactam) and oral (ceftibuten/VNRX-7145) broad-spectrum beta-lactam / beta-lactamase inhibitor combinations that are in Phase 3 and Phase 1, respectively. In addition, the first Venatorx antiviral compound (VNRX-9945), a Hepatitis B virus inhibitor, is in Phase 1 clinical development. The Company also has discovery-stage programs targeting a novel class of non-beta-lactam antibiotics called Penicillin Binding Protein (PBP) inhibitors that have the potential to circumvent 70+ years of resistance and usher in a new wave of antibacterial therapeutics.
Venatorx has received significant funding awards from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH); Wellcome Trust; the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Service (HHS); the U.S. Department of Defense’s Defense Threat Reduction Agency (DTRA); and CARB-X, and as well as private equity investments from Versant Ventures, Abingworth and Foresite Capital.
Venatorx Pharmaceuticals was founded in June 2010 by our three visionary, fearless leaders Drs. Christopher J. Burns, Daniel C. Pevear and Luigi Xerri. Fast forward to today, we have 80+ employees, three programs discovered in-house that are now clinical stage, with more in the pipeline!! Cheers to the many milestones to come as we work purposefully every day to get antibiotics and antiviral therapies into the hands of physicians to effectively treat patients. Below just a few of the highlights!
|You are using a browser that is not supported. Please consider changing your browser|